Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

por Falk, Markus, Schatz, Stefanie, Reich, Fabian P. M., Schmidt, Stefanie, Galster, Marco, Tiemann, Markus, Ficker, Joachim H., Brueckl, Wolfgang M.
Publicado 2023

Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung ca...

por Brueckl, Natalie F., Wirtz, Ralph M., Reich, Fabian P. M., Veltrup, Elke, Zeitler, Gloria, Meyer, Christian, Wuerflein, Dieter, Ficker, Joachim H., Eidt, Sebastian, Brueckl, Wolfgang M.
Publicado 2021

Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stag...

por Brueckl, Wolfgang M, Reck, Martin, Rittmeyer, Achim, Kollmeier, Jens, Wesseler, Claas, Wiest, Gunther H, Christopoulos, Petros, Tufman, Amanda, Hoffknecht, Petra, Ulm, Bernhard, Reich, Fabian, Ficker, Joachim H, Laack, Eckart
Publicado 2020

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with n...

por Brueckl, Wolfgang M., Reck, Martin, Rittmeyer, Achim, Kollmeier, Jens, Wesseler, Claas, Wiest, Gunther H., Christopoulos, Petros, Stenzinger, Albrecht, Tufman, Amanda, Hoffknecht, Petra, Ulm, Bernhard, Reich, Fabian, Ficker, Joachim H., Laack, Eckart
Publicado 2021